Compare RPID & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPID | RFL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 92.6M |
| IPO Year | 2021 | 2017 |
| Metric | RPID | RFL |
|---|---|---|
| Price | $2.11 | $1.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 218.3K | 172.5K |
| Earning Date | 05-08-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.78 | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,587,000.00 | $917,000.00 |
| Revenue This Year | $19.12 | N/A |
| Revenue Next Year | $18.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.74 | ★ 43.96 |
| 52 Week Low | $1.66 | $1.12 |
| 52 Week High | $4.94 | $3.96 |
| Indicator | RPID | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 42.22 |
| Support Level | $1.98 | $1.21 |
| Resistance Level | $2.17 | $3.96 |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 61.11 | 6.25 |
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.